Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
2004 1
2005 2
2006 1
2007 2
2010 2
2011 1
2012 2
2013 3
2014 4
2015 1
2016 1
2017 2
2018 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis.
Hérault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang YA, Wang X, Pietras EM, Chu SH, Barry-Holson K, Armstrong S, Göttgens B, Passegué E. Hérault A, et al. Nature. 2017 Apr 6;544(7648):53-58. doi: 10.1038/nature21693. Epub 2017 Mar 29. Nature. 2017. PMID: 28355185 Free PMC article.
Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia.
de Almeida PE, Mak J, Hernandez G, Jesudason R, Herault A, Javinal V, Borneo J, Kim JM, Walsh KB. de Almeida PE, et al. Among authors: herault a. Cancer Immunol Res. 2020 Jun;8(6):806-818. doi: 10.1158/2326-6066.CIR-19-0360. Epub 2020 Apr 1. Cancer Immunol Res. 2020. PMID: 32238381 Free article.
L'Epidermal Growth Factor Receptor (EGFR) est une cible thérapeutique pour un sous-groupe de tumeurs de vessie agressives de phénotype de type basal.
Neuzillet Y, Rebouissou S, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, Herault A, Kamoun A, Caillault A, Letouze E, Elarouci N, Decoux Y, Molinie V, Vordos D, Laplanche A, Maille P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Allory Y, Radvanyi F, Lebret T. Neuzillet Y, et al. Among authors: herault a. Prog Urol. 2014 Nov;24(13):806. doi: 10.1016/j.purol.2014.08.053. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461580 French. No abstract available.
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F. Rebouissou S, et al. Among authors: herault a. Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970. Sci Transl Med. 2014. PMID: 25009231 Free article.
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.
Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F. Vallot C, et al. Among authors: herault a. J Natl Cancer Inst. 2011 Jan 5;103(1):47-60. doi: 10.1093/jnci/djq470. Epub 2010 Dec 20. J Natl Cancer Inst. 2011. PMID: 21173382 Free PMC article.
PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y. Calderaro J, et al. Among authors: herault a. Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24. Int J Cancer. 2014. PMID: 24122582 Free article.
Fluorescent nanoparticles as selective Cu(II) sensors.
Méallet-Renault R, Hérault A, Vachon JJ, Pansu RB, Amigoni-Gerbier S, Larpent C. Méallet-Renault R, et al. Among authors: herault a. Photochem Photobiol Sci. 2006 Mar;5(3):300-10. doi: 10.1039/b513215k. Epub 2005 Dec 20. Photochem Photobiol Sci. 2006. PMID: 16520865
21 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page